Mirum Pharmaceuticals, Inc. (MIRM)
96.74
+0.44
(+0.45%)
USD |
NASDAQ |
Aug 24, 16:00
96.74
0.00 (0.00%)
After-Hours: 20:00
Mirum Pharmaceuticals Enterprise Value : 6.561B for Aug. 21, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 21, 2026 | 6.561B |
| August 20, 2026 | 6.610B |
| August 19, 2026 | 6.945B |
| August 18, 2026 | 6.856B |
| August 17, 2026 | 6.789B |
| August 14, 2026 | 6.842B |
| August 13, 2026 | 6.720B |
| August 12, 2026 | 6.733B |
| August 11, 2026 | 6.686B |
| August 10, 2026 | 6.716B |
| August 07, 2026 | 6.842B |
| August 06, 2026 | 6.419B |
| August 05, 2026 | 7.175B |
| August 04, 2026 | 7.081B |
| August 03, 2026 | 7.097B |
| July 31, 2026 | 7.185B |
| July 30, 2026 | 7.615B |
| July 29, 2026 | 7.290B |
| July 28, 2026 | 7.592B |
| July 27, 2026 | 7.720B |
| July 24, 2026 | 7.644B |
| July 23, 2026 | 7.730B |
| July 22, 2026 | 7.738B |
| July 21, 2026 | 7.904B |
| July 20, 2026 | 7.876B |
| Date | Value |
|---|---|
| July 17, 2026 | 8.021B |
| July 16, 2026 | 7.924B |
| July 15, 2026 | 8.160B |
| July 14, 2026 | 8.153B |
| July 13, 2026 | 8.033B |
| July 10, 2026 | 8.233B |
| July 09, 2026 | 8.594B |
| July 08, 2026 | 8.650B |
| July 07, 2026 | 8.633B |
| July 06, 2026 | 8.219B |
| July 02, 2026 | 8.457B |
| July 01, 2026 | 8.125B |
| June 30, 2026 | 7.905B |
| June 29, 2026 | 7.431B |
| June 26, 2026 | 7.478B |
| June 25, 2026 | 7.083B |
| June 24, 2026 | 6.942B |
| June 23, 2026 | 6.705B |
| June 22, 2026 | 6.504B |
| June 18, 2026 | 6.465B |
| June 17, 2026 | 6.154B |
| June 16, 2026 | 6.125B |
| June 15, 2026 | 6.091B |
| June 12, 2026 | 5.990B |
| June 11, 2026 | 6.002B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Incyte Corp. | 21.19B |
| Insmed, Inc. | 27.04B |
| Alnylam Pharmaceuticals, Inc. | 31.27B |
| BioMarin Pharmaceutical, Inc. | 16.25B |
| Ionis Pharmaceuticals, Inc. | 10.03B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -67.23M |
| Revenue (Quarterly) | 176.24M |
| Total Expenses (Quarterly) | 243.47M |
| EPS Diluted (Quarterly) | -1.061 |
| Gross Profit Margin (Quarterly) | 82.65% |
| Profit Margin (Quarterly) | -38.14% |
| Earnings Yield | -15.04% |
| Normalized Earnings Yield | -5.784 |